SAN DIEGO, California— June 1st, 2026 – At ASMS, Bruker Corporation (Nasdaq: BRKR) unveiled a broad set of platform, software, and workflow advances spanning extreme-resolution mass spectrometry, proteomics, metabolomics, and exposomics.
Headlining the launch was timsMRMS, a new system that integrates trapped ion mobility separation (TIMS) with magnetic resonance mass spectrometry (MRMS). The approach delivers mass resolving power from 1 to 10 million, parts-per-billion mass accuracy, and a four orders of magnitude single-acquisition dynamic range in a single acquisition, enabling molecular level characterization across applications ranging from petroleomics and energy research to complex biological samples.
In proteomics, Bruker reported major performance gains across its timsUltra AIP and timsOmni platforms. Instrument refinements, razor-PASEF workflows, and Spectronaut 21 software now enable identification and quantification of more than 10,000 proteins per sample, or over 6,500 proteins at throughputs of up to 500 samples per day. These capabilities are already being applied in translational oncology. Programs led by Stephan Singer at University Hospital Tübingen and Oliver Schilling at the University of Freiburg use deep proteomics on FFPE biopsies to uncover actionable tumor biology that can remain invisible at the DNA or RNA level.
For intact and top-down workflows, Bruker introduced a new argon collision gas option for timsOmni, delivering roughly four-fold gains in collision-induced dissociation (CID) sensitivity for biomolecules. The company also announced a partnership with Integrated Protein Technologies, integrating its SampleStream system directly with timsOmni for automated, high-throughput buffer exchange and MS-ready intact protein samples in under two minutes, with no carryover.
Bruker’s software portfolio also advanced with the release of OmniScape 2027, ProteoScape 2027, and GlycoScape 2027. New AI-driven tools include LYRA, a de novo sequencing algorithm for top-down proteoform identification and post-translational modification (PTM) analysis, expanded trapped electron dissociation workflows for glycoproteomics, and tims-Casanovo, a transformer-based model developed with academic collaborators to improve peptide sequencing across challenging datasets. All glycoproteomics workflows are now compatible with MSFragger.
Beyond proteomics, Bruker highlighted advances in 4D metabolomics and environmental health research. MetaboScape now supports dual EI/CI ionization for broader chemical exposure profiling, while an early-access hybrid metabolomics program on timsMetabo aims to combine absolute quantitation with untargeted discovery in a single experiment. Following its January 2026 acquisition of TOFWERK, Bruker also launched an Air Exposomics initiative that integrates real-time volatile organic compound (VOC) and aerosol monitoring with multi-omics analysis to link environmental exposures to human disease.
